Company Filing History:
Years Active: 2003-2005
Title: Douglas Ohlendorf: Innovator in Streptococcal Toxin Research
Introduction
Douglas Ohlendorf is a notable inventor based in Eden Prairie, MN (US). He has made significant contributions to the field of biotechnology, particularly in the development of vaccines and pharmaceutical compositions. With a total of 5 patents, Ohlendorf's work focuses on enhancing the safety and efficacy of treatments related to streptococcal toxins.
Latest Patents
Ohlendorf's latest patents include innovations related to mutants of Streptococcal toxin A. These inventions are directed towards mutant SPE-A toxins or fragments thereof, which can be utilized in vaccine and pharmaceutical compositions. The preferred SPE-A toxin features at least one amino acid change, rendering it substantially non-lethal compared to the wild type SPE-A toxin. This advancement allows for the creation of vaccine compositions that can effectively protect animals against the harmful biological activities of the wild type SPE-A toxin.
Career Highlights
Douglas Ohlendorf is affiliated with the University of Minnesota, where he continues to advance research in his field. His work has garnered attention for its potential applications in medical science, particularly in developing safer vaccines.
Collaborations
Ohlendorf collaborates with esteemed colleagues such as Patrick M Schlievert and Manuela Roggiani. Their combined expertise contributes to the innovative research being conducted at the University of Minnesota.
Conclusion
In summary, Douglas Ohlendorf is a prominent inventor whose work on streptococcal toxins has the potential to revolutionize vaccine development. His contributions to biotechnology are significant and continue to impact the field positively.